Pfizer Inc. (PFE)

42.65
0.25 0.59
NYSE : Health Technology
Prev Close 42.40
Open 42.24
Day Low/High 42.19 / 42.74
52 Wk Low/High 34.32 / 46.47
Volume 3.39M
Avg Volume 24.33M
Exchange NYSE
Shares Outstanding 5.78B
Market Cap 245.09B
P/E Ratio 10.73
Div & Yield 1.44 (3.29%)
Ochsner Health System And Pfizer Partner To Develop Innovative Models For Clinical Trials

Ochsner Health System And Pfizer Partner To Develop Innovative Models For Clinical Trials

Ochsner Health System, Louisiana's largest non-profit academic healthcare system, and Pfizer Inc (NYSE:PFE) have entered into a multi-year strategic alliance to develop innovative models for clinical trials.

Pfizer Receives European Approval For ZIRABEV™ (bevacizumab), A Biosimilar To Avastin®*

Pfizer Receives European Approval For ZIRABEV™ (bevacizumab), A Biosimilar To Avastin®*

Pfizer Inc. (NYSE: PFE) today announced the European Commission (EC) has approved ZIRABEV™ for the treatment of metastatic carcinoma of the colon or rectum, metastatic breast cancer, unresectable advanced, metastatic or recurrent non-small cell lung...

Pfizer And Lilly Announce Top-line Results From Phase 3 Study Of Tanezumab In Chronic Low Back Pain

Pfizer And Lilly Announce Top-line Results From Phase 3 Study Of Tanezumab In Chronic Low Back Pain

NEW YORK and INDIANAPOLIS, Feb. 19, 2019 /PRNewswire/ -- Pfizer Inc.

3 Pet Product Stocks Ready to Be Unleashed: Dogness, Elanco and Zoetis

3 Pet Product Stocks Ready to Be Unleashed: Dogness, Elanco and Zoetis

Pets can bring significant profits to companies that cater to this niche market.

IPO Explosion: Cramer's 'Mad Money' Recap (Wednesday 2/13/19)

IPO Explosion: Cramer's 'Mad Money' Recap (Wednesday 2/13/19)

Jim Cramer sees ripple effects of a storm of IPOs, and is worried about the lack of money coming into the market.

Stocks Mixed Ahead of U.S.-China Trade Talks; Healthcare Sector Weighs on Dow

Stocks Mixed Ahead of U.S.-China Trade Talks; Healthcare Sector Weighs on Dow

The Dow Jones Industrial Average falls as investors eye progress in this week's renewed U.S.-China trade talks.

Don't Be A Hero: Cramer's 'Mad Money' Recap (Thursday 2/7/19)

Don't Be A Hero: Cramer's 'Mad Money' Recap (Thursday 2/7/19)

Don't get too bearish, says Jim Cramer, but don't break discipline here. This is a perfectly reasonable decline.

Drugs, Defense, Shutdown, China: Trump's State of the Union Speech

Drugs, Defense, Shutdown, China: Trump's State of the Union Speech

Dramatic showdown or appeal for unity? Trump seeks to 'heal old wounds, build new coalitions.'

'Wonder Dogs' and 'Underdogs': 2 Hot Diggity Twists on the 'Dogs of the Dow'

'Wonder Dogs' and 'Underdogs': 2 Hot Diggity Twists on the 'Dogs of the Dow'

Selecting the creme de la creme of last year's top dividend dogs generated an average total return of 8.8%.

Pfizer Receives Positive CHMP Opinion For Vizimpro® (dacomitinib) For The First-line Treatment Of Adult Patients With Locally Advanced Or Metastatic Non-Small Cell Lung Cancer With EGFR-Activating Mutations

Pfizer Receives Positive CHMP Opinion For Vizimpro® (dacomitinib) For The First-line Treatment Of Adult Patients With Locally Advanced Or Metastatic Non-Small Cell Lung Cancer With EGFR-Activating Mutations

Pfizer today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending Vizimpro® (dacomitinib) 45 mg, as monotherapy, be granted marketing authorization in...

Pfizer's Near-Term Correction Could Be Over

Pfizer's Near-Term Correction Could Be Over

Pfizer may be done with its two-month correction but the uptrend may not resume right away.

What Boeing's Report Means for U.S. Companies With China Exposure

What Boeing's Report Means for U.S. Companies With China Exposure

Kate Warne, investment strategist at Edward Jones, talked to TheStreet about what Boeing's report means for U.S. companies with exposure to China, Apple's beat and how the healthcare sector is looking.

Watch Out for the Wave: Cramer's 'Mad Money' Recap (Tuesday 1/29/19)

Watch Out for the Wave: Cramer's 'Mad Money' Recap (Tuesday 1/29/19)

Jim Cramer says that if expectations are too high, even a great quarter cannot save you from the wave of selling.

Jim Cramer: When Is a Miss Not a Miss?

Jim Cramer: When Is a Miss Not a Miss?

When the stock's inexpensive, hated and devoid of love -- that's when.

Pfizer Tops Q4 Earnings But Guides for Weaker 2019 as Lyrica Exclusivity Ends

Pfizer Tops Q4 Earnings But Guides for Weaker 2019 as Lyrica Exclusivity Ends

Pfizer posted solid fourth quarter earnings Tuesday but issued weaker-than-expected 2019 guidance as the exclusivity of its key epilepsy treatment Lyrica comes to and end.

Dow Closes Modestly Higher Ahead of Apple Earnings

Dow Closes Modestly Higher Ahead of Apple Earnings

The Dow Jones Industrial Average posted modest gains Tuesday ahead of financial results from tech bellwether Apple Inc.

Sloppy Earnings, China's Economy, AMD Earnings Preview: Market Recon

Sloppy Earnings, China's Economy, AMD Earnings Preview: Market Recon

What we have seen of late from a number of chip producers really might be interpreted as pre-recessionary.

Apple, AMD, PG&E, Huawei and the Federal Reserve - 5 Things You Must Know

Apple, AMD, PG&E, Huawei and the Federal Reserve - 5 Things You Must Know

U.S. stock futures are mixed amid worries that a U.S. decision to pursue criminal charges against the chief financial officer of China's biggest tech company could stall progress in trade negotiations between the world's two biggest economies; the Fed begins a two-day meeting Tuesday; Apple, AMD, Verizon, Pfizer and 3M report earnings Tuesday; PG&E, the nation's largest utility, files for Chapter 11 bankruptcy protection.

PFIZER REPORTS FOURTH-QUARTER AND FULL-YEAR 2018 RESULTS

PFIZER REPORTS FOURTH-QUARTER AND FULL-YEAR 2018 RESULTS

Pfizer Inc. (NYSE: PFE) reported financial results for fourth-quarter and full-year 2018 and provided 2019 financial guidance.

Pfizer And Lilly Announce Top-Line Results From Second Phase 3 Study Of Tanezumab In Osteoarthritis Pain

Pfizer And Lilly Announce Top-Line Results From Second Phase 3 Study Of Tanezumab In Osteoarthritis Pain

Pfizer Inc. (NYSE:PFE) and Eli Lilly and Company (NYSE:LLY) today announced positive top-line results from a Phase 3 study evaluating tanezumab 2.

Stocks Mixed as US-China Tensions Escalate; Dollar Dips Ahead of Fed Meeting

Stocks Mixed as US-China Tensions Escalate; Dollar Dips Ahead of Fed Meeting

Global stocks were mixed Tuesday, with Wall Street futures drifting into the red, as investors worried that a U.S. decision to pursue criminal charges against the CFO of China's biggest tech company could stall progress in trade negotiations between the world's two biggest economies that are set to resume this week.

Earnings Preview: Apple, AMD, Verizon, Other Giants to Report Crucial Q4

Earnings Preview: Apple, AMD, Verizon, Other Giants to Report Crucial Q4

Eight important companies report earnings between Monday and Tuesday. Don't miss them.

Caterpillar Profit Warning Pounds Dow Futures as US Earnings Take Center Stage

Caterpillar Profit Warning Pounds Dow Futures as US Earnings Take Center Stage

U.S. equity futures fell sharply lower Monday as a profit warning from industrial equipment maker Caterpillar cast a pall over the busiest week of the fourth quarter earnings season as markets shifted focus to a series of major event risks and blue chip reports in the week ahead.

Stocks Drift Lower as Shutdown Rally Fades, Focus Shifts to Earnings and Fed

Stocks Drift Lower as Shutdown Rally Fades, Focus Shifts to Earnings and Fed

Global stocks drifted lower Monday as last week's late-hour rally on Wall Street, sparked by a surprise concession from President Donald Trump to end the 35-day government shutdown, fizzled in overnight trading as markets shifted focus to a series of major event risks and blue chip corporate earnings in the day ahead.

U.S. Earnings Season Hits Stride With FAANG Reports but 2019 Outlook Weakens

U.S. Earnings Season Hits Stride With FAANG Reports but 2019 Outlook Weakens

U.S. corporate earnings have come in largely ahead of analysts' forecasts in the first two weeks of the reporting season, according to data from Refinitiv, but the rate at which companies are beating estimates continues to slip below both near and longer-term averages, suggesting the fading impact of tax cuts, and concerns about slowing global growth, could dampen profits over the first half of the year.

The Earnings Super Bowl: Cramer's 'Mad Money' Recap (Friday 1/25/19)

The Earnings Super Bowl: Cramer's 'Mad Money' Recap (Friday 1/25/19)

Jim Cramer's plan for getting through the heart of earnings season next week.

TheStreet Quant Rating: B (Buy)